Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

Oxford Immunotec Announces US FDA Approval Of PMA Supplement For The Use Of The T-Cell Xtend® Reagent

Oxford Immunotec announces US FDA approval of PMA supplement for the use of the T-Cell Xtend® reagent.

Oxford, UK [Marlborough, MA]; 11 August 2010 –  Oxford Immunotec Ltd, the T-cell measurement company, today announces that it has received approval of a PMA supplement for the use of the T-Cell Xtend reagent. Use of this product enables customers to store whole blood overnight prior to processing in the T-SPOT®.TB assay.

Interferon Gamma Release Assays (IGRA) performance (such as the T-SPOT.TB test) is affected by blood storage time and, therefore, the tests have been limited by the need to process the blood sample on the same day as phlebotomy (typically 8 – 16 hours with current commercial tests). The T-Cell Xtend reagent removes this time constraint by allowing blood to be drawn and shipped to any local or centralized laboratory overnight with no impact on the performance of blood in the T-SPOT.TB assay. The T-Cell Xtend reagent works by reversing the degradation that the sample would otherwise suffer during storage.

Commenting on the approval, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec, said, “This is our fourth PMA supplement to be approved by the FDA in the last 12 months and represents another significant milestone for Oxford Immunotec. The use of T-Cell Xtend reagent allows much greater flexibility to
T-SPOT.TB test customers in processing samples as they can be shipped to the laboratory overnight rather than having to be processed on the same day as collection”.
– Ends –